NasdaqGS:IONSBiotechs
Why Ionis Pharmaceuticals (IONS) Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal
Earlier this week, Ionis Pharmaceuticals announced that the FDA approved TRYNGOLZA (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia, while also licensing ex-US rights to its investigational Alexander disease therapy zilganersen to Recordati for US$30,000,000 upfront plus potential milestones and tiered royalties.
This pairing of a first-in-class U.S. approval in a larger metabolic population with an out-licensing deal in a rare...